[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"head-and-neck-tumor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:head-and-neck-tumor":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,108],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100585684","topical-diclofenac-for-prevention-of-radiation-induced-dermatitis-100585684",false,"NCT06905561","Topical Diclofenac for Prevention of Radiation-induced Dermatitis","Topical Diclofenac for Prevention of Radiation-induced Dermatitis: A Single-center, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Male and female which are 18 years of age or older\n2. Performance status \\\u003C 2\n3. Epithelial carcinoma of oropharynx, nasopharynx, larynx, hypopharynx, paranasal sinus and salivary glands or breast cancer, planned to receive a total dose of at least 50 Gy\n4. The RTOG radiation dermatitis rating should be equal to 0 and the skin nutrition should be good\n5. The main organs are functioning normally and meet the following standards: (1) Blood routine examination must meet the following criteria: (no blood transfusion within 14 days) a. HB ≥ 100g\u002FL, b. WBC ≥3×10\\^9\u002FL c. ANC≥1.5×10\\^9\u002FL, d. PLT ≥100×10\\^9\u002FL; (2) Biochemical examination must meet the following standards: a. BIL\\\u003C1.5 times the upper limit of normal value (ULN), b. ALT and AST\\\u003C2.5ULN, GPT ≤1.5×ULN; c. Serum Cr≤1 ULN, endogenous creatinine clearance rate\\>60ml\u002Fmin (Cockcroft Gault formula);(3).Good coagulation function: defined as International standardized ratio (INR) or prothrombin time (PT) ≤1.5×ULN;(4).The myocardial enzyme spectra were in the normal range.\n6. Patients willing and able to give signed informed consent and, in the opinion of the Investigator, to comply with the Clinical Investigation Plan tests and procedures.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women\n2. A known history of intolerance or allergy to any component of the investigational product;\n3. severe cardiopulmonary disease (such as unstable angina attacks, grade II cardiac insufficiency, acute myocardial infarction, acute episodes of chronic obstructive pulmonary disease, pulmonary heart disease);\n4. The acute phase is accompanied by inflammatory skin diseases, such as atopic dermatitis, contact dermatitis, psoriasis, lichen planus, pityriasis rosea.\n5. Systemic diseases known to delay the skin healing process, such as diabetes or severe kidney failure;\n6. Skin rupture caused by malignant tumors.","ALL","18 Years","75 Years",{"count":20,"type":21},156,"ESTIMATED","INTERVENTIONAL",[24],"NA","Radiation induced dermatitis (RID) is one of the leading adverse events of radiation therapy, and if occurred could alter the course of therapy. The main pathways of RID is inflammation and oxidative stress on local and systemic bases. The Diclofenac is a COX-2 inhibitor and Nonsteroidal anti-inflammatory drugs whose anti-inflammatory and antioxidant activities have been proven in several clinical trials. Thus, the aim of the present study is to evaluate the efficacy of Diclofenac sodium gel as a prophylactic method against the development of RID.",[27,28],"Head and Neck Tumor","Breast Cancer",[30,31,32,33,34],"Topical Diclofenac","Radiation-induced dermatitis","Prevention","Head and Neck tumor","Brest Cancer","RECRUITING","2026-03-30",{"date":38,"type":39},"2026-04-03","ACTUAL",{"date":41,"type":39},"2025-02-13",{"date":43,"type":21},"2026-08-31",{"name":45,"class":46},"The Second Affiliated Hospital of Hainan Medical University","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":58,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100368284","the-momentum-study-the-multiple-outcome-evaluation-of-radiation-therapy-using-the-mr-linac-study-100368284","NCT04075305","The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study","The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study","MOMENTUM","Inclusion Criteria:\n\n* Patient is to undergo or has completed imaging or treatment procedures on an MR-Linac;\n* Patient provides written, informed consent;\n* Patient is 18 years old or older.\n\nExclusion Criteria:\n\n* MRI exclusion criteria, including\n* MRI contraindications as per usual clinical care, such as (possible) pregnancy; claustrophobia and metal or electronic implants not compatible with MRI.",{"count":57,"type":21},8000,"2 Years","OBSERVATIONAL","The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose to improve patients' survival, local, and regional tumor control and quality of life.",[62,28,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,27,90,91,92,93,94,95,96,97],"Oncology","Prostate Cancer","Gynecologic Cancer","Brain Tumor","Brain Cancer","Gynecologic Tumor","Prostate Tumor","Prostate Neoplasm","Breast Tumor","Radiation Toxicity","Quality of Life","Rectal Cancer","Rectal Tumor","Rectal Neoplasms","Lung Cancer","Lung Tumor","Lung Neoplasm","Esophageal Cancer","Esophagus Cancer","Esophageal Tumor","Esophageal Neoplasm","Esophagus Tumor","Esophagus Neoplasm","Pancreatic Cancer","Pancreatic Tumor","Pancreatic Neoplasms","Head and Neck Cancer","Head and Neck Neoplasms","Tumor","Neoplasms","Bladder Cancer","Bladder Neoplasm","Liver Cancer","Liver Neoplasms","Liver Metastases","Oligometastases","2026-03-03",{"date":100,"type":39},"2026-03-05",{"date":102,"type":39},"2019-02-01",{"date":104,"type":21},"2030-08-01",{"name":106,"class":46},"UMC Utrecht",18,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":119,"conditions":120,"keywords":125,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":141},"100443348","a-study-evaluating-the-integrative-medicine-at-home-imhome-program-in-people-with-cancer-100443348","NCT05053230","A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer","Integrative Medicine for Patient-reported Outcomes, Values, and Experience (IMPROVE)","IMPROVE","Inclusion Criteria:\n\n* Age ≥ 18 years or older\n* Karnofsky score 60 or greater\n* Life expectancy greater than six months\n* English speaking\n\nAdditional Inclusion Criteria for Head and Neck, Thoracic, Gynecologic, Melanoma and Breast Baskets\n\n* Patients with a diagnosis of head and neck tumors, thoracic tumors, gynecological tumors, melanoma, breast cancer, or gynecologic cancer\n* Actively receiving systemic oncological treatment or radiotherapy, or within 4 weeks of radiotherapy completion or primary cytoreductive surgery\n* Worst fatigue over the last 7 days rated 4 or greater on (0-10 scale)\n\nAdditional Inclusion Criteria for First Remission Gynecologic Cancer Basket\n\n* Patients with a diagnosis or clinical suspicion of gynecologic malignancy who have completed definitive first line treatment (maintenance hormonal or targeted therapies are allowed)\n\nAdditional Inclusion Criteria for the Advanced Cancer Basket:\n\n* Patients with a diagnosis of Stage III or IV lung cancer; any stage pancreatic cancer, unresectable cholangiocarcinoma, unresectable liver cancer, unresectable ampullary or peri-ampullary cancer, or other stage IV gastrointestinal cancer; stage III or IV ovarian or fallopian tube cancers or other stage IV gynecologic cancer; stage IV breast cancer; stage III testicular cancer or any stage IV genitourinary cancer; stage IV sarcoma; stage IV melanoma; stage IV endocrine cancer; lymphoma, myeloma, or Leukemia\n* Actively receiving oncological treatment, radiotherapy or active surveillance\n\nAdditional Inclusion Criteria for the Cancer Survivor Basket:\n\n* Completed active cancer treatment (e.g., surgery, radiation, chemotherapy) (maintenance hormonal or targeted therapies are allowed).\n* Worst fatigue over the last 7 days rated 4 or greater on (0-10 scale)\n\nExclusion Criteria:\n\n* Cognitive impairment that would preclude response to study assessments or require the use of Legally Authorized Representatives\n* Unwilling to accept random assignment\n* Concurrently enroll onto ongoing competing trials of integrative medicine interventions with symptom\u002Ftoxicity as primary outcome. Note, however, patient will be allowed to enroll on other therapeutic protocols",{"count":117,"type":21},480,[24],"The overarching long-term goal of the Integrative Medicine for Patient-reported Outcomes Values and Experience (IMPROVE) research program is to evaluate whether integrating a virtual mind-body programming, Integrative Medicine at Home (IM@Home), will improve patient perceived values, outcomes, and experiences as they undergo systemic cancer treatment such as chemotherapy, immunotherapy, radiotherapy, targeted agents, cytoreductive surgery.",[88,27,121,122,64,67,123,124],"Thoracic Tumor","Thoracic Cancer","Melanoma","Ovarian Cancer",[88,126,127,128,129,130,131,132],"head and neck tumor","thoracic tumors","gynecological tumors","melanoma","21-369","Memorial Sloan Kettering Cancer Center","ovarian cancer","2025-10-08",{"date":135,"type":39},"2025-10-09",{"date":137,"type":39},"2021-09-20",{"date":139,"type":21},"2026-09-20",{"name":131,"class":46},7]